heiDATA

Metrics

209,782 Downloads

Featured Dataverses

In order to use this feature you must have at least one published dataverse.

Publish Dataverse

Are you sure you want to publish your dataverse? Once you do so it must remain published.

Publish Dataverse

This dataverse cannot be published because the dataverse it is in has not been published.

Delete Dataverse

Are you sure you want to delete your dataverse? You cannot undelete this dataverse.

File Type: Document

61 to 70 of 967 Results

Vardarli_Suppl Fig 43.pdf Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data] Adobe PDF - 64.6 KB - MD5: 753d4e08425c46578df825f5e795a91c Suppl. Fig. 43. Funnel plot for trials investigating adrenal insufficiency grade3-5 under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.
Vardarli_Suppl Fig 42.pdf Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data] Adobe PDF - 70.1 KB - MD5: b5a0ac42aea01ae65c1000f3ad49c2b0 Suppl. Fig. 42. Galbraith plot for trials investigating adrenal insufficiency any grade under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.
Vardarli_Suppl Fig 41.pdf Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data] Adobe PDF - 64.2 KB - MD5: ad6c63c17fd489fa8c647b90891930e3 Suppl. Fig. 41. Funnel plot with trim-and-fill for trials investigating adrenal insufficiency any grade under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.
Vardarli_Suppl Fig 40.pdf Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data] Adobe PDF - 67.1 KB - MD5: 23a3912a62f8977ad3197d69d3b0cd41 Suppl. Fig. 40. Funnel plot for subgroups of ICI types trials investigating adrenal insufficiency any grade under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.
Vardarli_Suppl Fig 4.pdf Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data] Adobe PDF - 81.0 KB - MD5: df108cf5375705ae0e54343a1fb8acac Suppl. Fig. 4. Forest plot for cumulative meta-analysis for trials investigating hypothyroidism any grade under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.
Vardarli_Suppl Fig 39.pdf Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data] Adobe PDF - 64.4 KB - MD5: 5bf15c23af6441a53ca79acff68d604c Suppl. Fig. 39. Funnel plot for trials investigating adrenal insufficiency any grade under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.
Vardarli_Suppl Fig 38.pdf Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data] Adobe PDF - 71.3 KB - MD5: 1dd5eec104223934185b7fef6e56cc4d Suppl. Fig. 38. Galbraith plot for trials investigating hypophysitis/hypopituitarism grade 3-5 under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.
Vardarli_Suppl Fig 37.pdf Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data] Adobe PDF - 64.0 KB - MD5: de822d4b8ef9cacb467052fdc63730d2 Suppl. Fig. 37. Funnel plot with trim-and-fill for trials investigating hypophysitis/hypopituitarism grade 3-5 under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.
Vardarli_Suppl Fig 36.pdf Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data] Adobe PDF - 66.8 KB - MD5: 556e803b091dfed445b705972e835632 Suppl. Fig. 36. Funnel plot for subgroups of ICI types trials investigating hypophysitis/hypopituitarism grade 3-5 under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.
Vardarli_Suppl Fig 35.pdf Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data] Adobe PDF - 64.1 KB - MD5: ba984fd679c86b272e1d13f3d8ad2365 Suppl. Fig. 35. Funnel plot for trials investigating hypophysitis/hypopituitarism grade 3-5 under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.

Vardarli_Suppl Fig 43.pdf

Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data]

Adobe PDF - 64.6 KB -

Suppl. Fig. 43. Funnel plot for trials investigating adrenal insufficiency grade3-5 under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.

Vardarli_Suppl Fig 42.pdf

Adobe PDF - 70.1 KB -

Suppl. Fig. 42. Galbraith plot for trials investigating adrenal insufficiency any grade under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.

Vardarli_Suppl Fig 41.pdf

Adobe PDF - 64.2 KB -

Suppl. Fig. 41. Funnel plot with trim-and-fill for trials investigating adrenal insufficiency any grade under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.

Vardarli_Suppl Fig 40.pdf

Adobe PDF - 67.1 KB -

Suppl. Fig. 40. Funnel plot for subgroups of ICI types trials investigating adrenal insufficiency any grade under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.

Vardarli_Suppl Fig 4.pdf

Adobe PDF - 81.0 KB -

Suppl. Fig. 4. Forest plot for cumulative meta-analysis for trials investigating hypothyroidism any grade under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.

Vardarli_Suppl Fig 39.pdf

Adobe PDF - 64.4 KB -

Suppl. Fig. 39. Funnel plot for trials investigating adrenal insufficiency any grade under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.

Vardarli_Suppl Fig 38.pdf

Adobe PDF - 71.3 KB -

Suppl. Fig. 38. Galbraith plot for trials investigating hypophysitis/hypopituitarism grade 3-5 under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.

Vardarli_Suppl Fig 37.pdf

Adobe PDF - 64.0 KB -

Suppl. Fig. 37. Funnel plot with trim-and-fill for trials investigating hypophysitis/hypopituitarism grade 3-5 under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.

Vardarli_Suppl Fig 36.pdf

Adobe PDF - 66.8 KB -

Suppl. Fig. 36. Funnel plot for subgroups of ICI types trials investigating hypophysitis/hypopituitarism grade 3-5 under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.

Vardarli_Suppl Fig 35.pdf

Adobe PDF - 64.1 KB -

Suppl. Fig. 35. Funnel plot for trials investigating hypophysitis/hypopituitarism grade 3-5 under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.

Add Data

Share Dataverse

Link Dataverse

Reset Modifications